Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$407.90 USD
-4.32 (-1.05%)
Updated Oct 15, 2025 04:00 PM ET
After-Market: $407.10 -0.80 (-0.20%) 7:04 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VRTX 407.90 -4.32(-1.05%)
Will VRTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Other News for VRTX
VRTX's price rises by 1.19% on October 14, though its technical setup remains stable.
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
VRTX forms Non-ADX 1,2,3,4 Bullish on October 13
Vertex Pharmaceuticals (VRTX) Gets a Buy from Wells Fargo
Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)